Background: Acanthosis nigricans is a common hyperpigmentation disorder with a profound aesthetic impact. The primary concern of most patients is the cosmetic improvement, that is way there is a continuous search for the most effective cosmetic therapeutic option.
Methods: 40 acanthosis nigricans patients were included, lesions are split into equal halves; right side treated with TCA 15% peel and left side was treated with microneedling followed by TCA 15% peel, both sides were treated monthly for three months. Response to treatment was assessed by acanthosis nigricans grade improvement along with the percentage of improvement in texture and pigmentation individually.
Results: There was statistically significant improvement in acanthosis nigricans grade after treatment in both sides. The combination side showed more improvement in terms of texture and pigmentation.
Conclusion: Both TCA 15% alone or combined with microneedling were effective in improving acanthosis nigricans with superior results in combination modality.
{"title":"Trichloroacetic Acid 15% Peel Alone versus in Combination with Microneedling in Patients with Acanthosis Nigricans.","authors":"Shrook A Khashaba, Salma Alaa, Fatma Eldeeb","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Acanthosis nigricans is a common hyperpigmentation disorder with a profound aesthetic impact. The primary concern of most patients is the cosmetic improvement, that is way there is a continuous search for the most effective cosmetic therapeutic option.</p><p><strong>Methods: </strong>40 acanthosis nigricans patients were included, lesions are split into equal halves; right side treated with TCA 15% peel and left side was treated with microneedling followed by TCA 15% peel, both sides were treated monthly for three months. Response to treatment was assessed by acanthosis nigricans grade improvement along with the percentage of improvement in texture and pigmentation individually.</p><p><strong>Results: </strong>There was statistically significant improvement in acanthosis nigricans grade after treatment in both sides. The combination side showed more improvement in terms of texture and pigmentation.</p><p><strong>Conclusion: </strong>Both TCA 15% alone or combined with microneedling were effective in improving acanthosis nigricans with superior results in combination modality.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 4","pages":"28-32"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Post-liposuction skin irregularities (PLSI) represent a complication of liposuction, even though literature does not report specific data on their characteristics.
Objective: Considering the expanding request of treatment of PLSI and their similarities to cellulite, the aim of this study is to provide a definition or classification of their appearance according to a previously described cellulite scale and to highlight eventual novel features, in patients undergoing previous liposuction and a control group.
Methods: A total of 47 women, of which 47 percent performed a previous liposuction, were included in this study. Pictures of gluteal area and postero-lateral thighs were analyzed according to number and depth of depressions, skin laxity, asymmetry and v-sign by three investigators. The correlation between parameters and previous liposuction was explored with statistical analysis.
Results: Our results show good to excellent intraobserver agreement and moderate to good agreement between the evaluators. Additionally, we showed that PLSI can appear as marked cellulite signs (depth of evident depression) or as specific previously not reported features including asymmetry and v-sign.
Conclusion: Our findings provide information about the previously unreported morphology of PLSI. Further studies will apply validated features of PLSI proposed herein to clinical practice.
背景:吸脂术后皮肤不规则(PLSI)是吸脂术后的一种并发症,尽管文献中没有关于其特征的具体数据:考虑到 PLSI 治疗要求的不断扩大及其与橘皮组织的相似性,本研究的目的是根据之前描述的橘皮组织量表对其外观进行定义或分类,并突出曾接受过吸脂手术的患者和对照组的最终新特征:本研究共纳入了 47 名女性,其中 47% 曾进行过吸脂手术。三名研究人员根据凹陷的数量和深度、皮肤松弛程度、不对称程度和 V 形征对臀部和大腿后外侧的照片进行了分析。统计分析探讨了参数与之前吸脂手术之间的相关性:结果:我们的结果显示,观察者内部的一致性良好至极佳,评估者之间的一致性中等至良好。此外,我们还发现 PLSI 可表现为明显的橘皮组织迹象(凹陷深度明显),也可表现为以前未报道过的特定特征,包括不对称和 V 形征:结论:我们的研究结果提供了以前未报道过的 PLSI 形态学信息。进一步的研究将把本文提出的 PLSI 验证特征应用到临床实践中。
{"title":"From Cellulite to Post-liposuction Skin Irregularities: A Proposal for Definition and Classification.","authors":"Stefania Guida, Nicola Zerbinati, Claudio Conforti, Alessia Paganelli, Giovanni Pellacani, Hassan Galadari","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Post-liposuction skin irregularities (PLSI) represent a complication of liposuction, even though literature does not report specific data on their characteristics.</p><p><strong>Objective: </strong>Considering the expanding request of treatment of PLSI and their similarities to cellulite, the aim of this study is to provide a definition or classification of their appearance according to a previously described cellulite scale and to highlight eventual novel features, in patients undergoing previous liposuction and a control group.</p><p><strong>Methods: </strong>A total of 47 women, of which 47 percent performed a previous liposuction, were included in this study. Pictures of gluteal area and postero-lateral thighs were analyzed according to number and depth of depressions, skin laxity, asymmetry and v-sign by three investigators. The correlation between parameters and previous liposuction was explored with statistical analysis.</p><p><strong>Results: </strong>Our results show good to excellent intraobserver agreement and moderate to good agreement between the evaluators. Additionally, we showed that PLSI can appear as marked cellulite signs (depth of evident depression) or as specific previously not reported features including asymmetry and v-sign.</p><p><strong>Conclusion: </strong>Our findings provide information about the previously unreported morphology of PLSI. Further studies will apply validated features of PLSI proposed herein to clinical practice.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 4","pages":"24-27"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11022845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140861552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ramesh Gopal, Michael Marquardt, Gaurav Singh, Stanislav N Tolkachjov, Sarah T Arron
Early identification and intervention in patients with cutaneous squamous cell carcinoma (cSCC) who are at high risk for metastasis is important for optimal outcomes. Prognostic tools (e.g., American Joint Committee on Cancer, 8th edition [AJCC-8]) and management guidelines (National Comprehensive Cancer Network® [NCCN]) are useful in helping to identify high-risk patients with cSCC who might benefit from adjuvant therapies, such as radiation and/or immunotherapies; however, traditional staging and management guidelines rely on clinicopathologic risk factors to predict risk, which limits their prognostic accuracy. Gene expression profiling (GEP) is a clinically available, objective metric that can be used in conjunction with traditional clinicopathological staging to help clinicians stratify risk in patients with cSCC. The validated 40-GEP test can accurately classify patients with at least one high-risk feature as being at low (Class 1), higher (Class 2A), or highest (Class 2B) biological risk of nodal or distant metastasis within three years of diagnosis. A multidisciplinary panel comprising radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cSCC management convened in June 2023 to discuss the utility of 40-GEP testing in cSCC clinical decision-making in regard to adjuvant radiation therapy (ART). The panel identified gaps in clinical practice in which 40-GEP testing has particular utility: in escalation of care for lower-stage patients with high-risk tumors; in de-escalation of care for patients for whom the risks of ART may outweigh the benefits; and in decision-making regarding elective radiation to the nodal basin. The expert panel developed a risk-based clinical workflow for ART in patients with cSCC, utilizing 40-GEP testing within NCCN management guidelines and AJCC-8 staging.
{"title":"Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.","authors":"Ramesh Gopal, Michael Marquardt, Gaurav Singh, Stanislav N Tolkachjov, Sarah T Arron","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Early identification and intervention in patients with cutaneous squamous cell carcinoma (cSCC) who are at high risk for metastasis is important for optimal outcomes. Prognostic tools (e.g., American Joint Committee on Cancer, 8th edition [AJCC-8]) and management guidelines (National Comprehensive Cancer Network® [NCCN]) are useful in helping to identify high-risk patients with cSCC who might benefit from adjuvant therapies, such as radiation and/or immunotherapies; however, traditional staging and management guidelines rely on clinicopathologic risk factors to predict risk, which limits their prognostic accuracy. Gene expression profiling (GEP) is a clinically available, objective metric that can be used in conjunction with traditional clinicopathological staging to help clinicians stratify risk in patients with cSCC. The validated 40-GEP test can accurately classify patients with at least one high-risk feature as being at low (Class 1), higher (Class 2A), or highest (Class 2B) biological risk of nodal or distant metastasis within three years of diagnosis. A multidisciplinary panel comprising radiation oncologists and dermatologists/Mohs micrographic surgeons with expertise in cSCC management convened in June 2023 to discuss the utility of 40-GEP testing in cSCC clinical decision-making in regard to adjuvant radiation therapy (ART). The panel identified gaps in clinical practice in which 40-GEP testing has particular utility: in escalation of care for lower-stage patients with high-risk tumors; in de-escalation of care for patients for whom the risks of ART may outweigh the benefits; and in decision-making regarding elective radiation to the nodal basin. The expert panel developed a risk-based clinical workflow for ART in patients with cSCC, utilizing 40-GEP testing within NCCN management guidelines and AJCC-8 staging.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3 Suppl 2","pages":"S3-S8"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10939503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stefano Veraldi, Valentina Rosca, Remus Ioan Orasan, Magda Constantin, Roni P Dodiuk-Gad
Objective: Psoriasis is a chronic, inflammatory skin disease, requiring local and systemic drugs according to disease severity. This study aims to investigate the efficacy and safety of a topical treatment containing xyloglucan, pea proteins and Opuntia ficus-indica extracts (XPO) compared to calcipotriol 50mcg/betamethasone 0.5mg ointment (CB).
Methods: Forty-two patients diagnosed with mild-to-moderate plaque psoriasis were assigned 1:1 to XPO treatment or CB for 28 days. Disease status was assessed at baseline (V1), monitored every two weeks (V2, V3), and at follow-up (V4). Disease severity was assessed by PASI (Psoriasis Area and Severity Index), PGA (Physician's Global Assessment), and VAS (Visual Analog Scale for itching). Photos were taken before and after XPO treatment. Treatment efficacy was determined by comparing psoriasis severity at baseline to V3. Tolerability was assessed by monitoring the occurrence of adverse events.
Results: Both groups showed a statistically significant difference in PASI score from V1 to V2 (p=0.001, XPO; p=0.008, CB) and to V3 (p=0.001, XPO; p=0.004, CB). XPO achieved a PASI 50 score of 24 percent at V2 and 52 percent at V3 compared to CB (0% at V2 and 19% at V3). At V3, PGA was significantly reduced in both groups (p=0.003, XPO; p=0.001 CB). Both treatments significantly reduced itching at V2 (p=0.001, XPO; p=0.003, CB) and V3 (p=0.001, XPO; p=0.0005, CB).
Conclusion: XPO showed similar efficacy to CB, significantly reducing disease severity, erythema, itching, induration, and scaling with an excellent tolerability profile.
{"title":"A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and <i>Opuntia ficus-indica</i> Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-moderate Psoriasis.","authors":"Stefano Veraldi, Valentina Rosca, Remus Ioan Orasan, Magda Constantin, Roni P Dodiuk-Gad","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Psoriasis is a chronic, inflammatory skin disease, requiring local and systemic drugs according to disease severity. This study aims to investigate the efficacy and safety of a topical treatment containing xyloglucan, pea proteins and <i>Opuntia ficus-indica</i> extracts (XPO) compared to calcipotriol 50mcg/betamethasone 0.5mg ointment (CB).</p><p><strong>Methods: </strong>Forty-two patients diagnosed with mild-to-moderate plaque psoriasis were assigned 1:1 to XPO treatment or CB for 28 days. Disease status was assessed at baseline (V1), monitored every two weeks (V2, V3), and at follow-up (V4). Disease severity was assessed by PASI (Psoriasis Area and Severity Index), PGA (Physician's Global Assessment), and VAS (Visual Analog Scale for itching). Photos were taken before and after XPO treatment. Treatment efficacy was determined by comparing psoriasis severity at baseline to V3. Tolerability was assessed by monitoring the occurrence of adverse events.</p><p><strong>Results: </strong>Both groups showed a statistically significant difference in PASI score from V1 to V2 (<i>p</i>=0.001, XPO; <i>p</i>=0.008, CB) and to V3 (<i>p</i>=0.001, XPO; <i>p</i>=0.004, CB). XPO achieved a PASI 50 score of 24 percent at V2 and 52 percent at V3 compared to CB (0% at V2 and 19% at V3). At V3, PGA was significantly reduced in both groups (<i>p</i>=0.003, XPO; <i>p</i>=0.001 CB). Both treatments significantly reduced itching at V2 (<i>p</i>=0.001, XPO; <i>p</i>=0.003, CB) and V3 (<i>p</i>=0.001, XPO; <i>p</i>=0.0005, CB).</p><p><strong>Conclusion: </strong>XPO showed similar efficacy to CB, significantly reducing disease severity, erythema, itching, induration, and scaling with an excellent tolerability profile.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"12-17"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140145038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical Tips for Non-Invasive Cosmetic Procedures in Skin of Color Patients.","authors":"Archana M Sangha","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3-4 Suppl 1","pages":"S24-S25"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Faraz Yousefian, Ciaran Smythe, Haowei Han, Boni E Elewski, Mark Nestor
Background: Onychomycosis is a fungal infection of the nail unit that affects a large patient population globally. Onychomycosis, or tinea unguium, has a benign chronic clinical course; however, it can cause complications in certain patient populations suffering from diabetes and peripheral vascular disease. As nails grow slowly, onychomycosis requires a lengthy treatment plan, and choosing appropriate treatments can be challenging. There are a variety of treatment modalities available for patients including topical, oral, laser, light therapy, procedures such as avulsion and matrixectomy, supplements, over-the-counter medication, and plasma therapy that can be used as monotherapy or in combination for patient satisfaction.
Objective: We sought to review treatment options for onychomycosis, taking into consideration the efficacy, side effect profiles, practicality of treatment (adherence), and costs to help healthcare providers offer ethically appropriate treatment regimens to their patients.
Methods: A literature search was conducted using electronic databases (PubMed, Embase, Medline, CINAHL, EBSCO) and textbooks, in addition to the clinical experiences of the authors and other practitioners in treating onychomycosis, and a summary of the findings are presented here.
Results: Although topical (efinaconazole, tavaborole, ciclopirox), oral (terbinafine, itraconazole), and laser (1064nm Nd:YAG lasers, both short-pulsed and Q-switched lasers, carbon dioxide lasers, and the diode 870, 930nm) are the current Food and Drug Administration (FDA)-approved treatments for onychomycosis, they are just a fraction of available treatment options. New and emerging therapies including new topical and oral medications, combination therapy, photodynamic light therapy, procedural, supplements, over-the-counter medication, and plasma therapy are discussed in our review.
Discussion: Onychomycosis has high reinfection and recurrence rates, and the treatment remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, adherence, budget, the extent of quality of life discomfort, and aesthetic goals, independent of potential financial benefits to the clinicians.
{"title":"Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.","authors":"Faraz Yousefian, Ciaran Smythe, Haowei Han, Boni E Elewski, Mark Nestor","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Onychomycosis is a fungal infection of the nail unit that affects a large patient population globally. Onychomycosis, or tinea unguium, has a benign chronic clinical course; however, it can cause complications in certain patient populations suffering from diabetes and peripheral vascular disease. As nails grow slowly, onychomycosis requires a lengthy treatment plan, and choosing appropriate treatments can be challenging. There are a variety of treatment modalities available for patients including topical, oral, laser, light therapy, procedures such as avulsion and matrixectomy, supplements, over-the-counter medication, and plasma therapy that can be used as monotherapy or in combination for patient satisfaction.</p><p><strong>Objective: </strong>We sought to review treatment options for onychomycosis, taking into consideration the efficacy, side effect profiles, practicality of treatment (adherence), and costs to help healthcare providers offer ethically appropriate treatment regimens to their patients.</p><p><strong>Methods: </strong>A literature search was conducted using electronic databases (PubMed, Embase, Medline, CINAHL, EBSCO) and textbooks, in addition to the clinical experiences of the authors and other practitioners in treating onychomycosis, and a summary of the findings are presented here.</p><p><strong>Results: </strong>Although topical (efinaconazole, tavaborole, ciclopirox), oral (terbinafine, itraconazole), and laser (1064nm Nd:YAG lasers, both short-pulsed and Q-switched lasers, carbon dioxide lasers, and the diode 870, 930nm) are the current Food and Drug Administration (FDA)-approved treatments for onychomycosis, they are just a fraction of available treatment options. New and emerging therapies including new topical and oral medications, combination therapy, photodynamic light therapy, procedural, supplements, over-the-counter medication, and plasma therapy are discussed in our review.</p><p><strong>Discussion: </strong>Onychomycosis has high reinfection and recurrence rates, and the treatment remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, adherence, budget, the extent of quality of life discomfort, and aesthetic goals, independent of potential financial benefits to the clinicians.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"24-33"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941855/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Becker's nevus syndrome is defined by the association of a Becker nevus with homolateral breast hypoplasia or more rarely skeletal cutaneous or muscle deformities. Early diagnosis is important, especially in female patients to prevent and treat breast hypoplasia. We report two cases of Becker nevus syndrome with serious functional impairment and discuss possible treatment options.
{"title":"Becker Nevus Syndrome: A Rare Entity but Important to Recognize.","authors":"Noureddine Litaiem, Amel Chabbouh, Ines Chabchoub, Radhi Ben Naceur, Mourad Mokni, Faten Zeglaoui","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Becker's nevus syndrome is defined by the association of a Becker nevus with homolateral breast hypoplasia or more rarely skeletal cutaneous or muscle deformities. Early diagnosis is important, especially in female patients to prevent and treat breast hypoplasia. We report two cases of Becker nevus syndrome with serious functional impairment and discuss possible treatment options.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"21-23"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Acne vulgaris is a common skin condition treated with various medications targeting different aspects of its pathogenesis. Though increasing in popularity, the United States Food and Drug Administration (FDA) does not evaluate the safety or efficacy of dietary supplements marketed for the treatment of acne, calling into question the veracity of their labels. This review aimed to assess the safety and effectiveness of ingredients in popular acne supplements.
Methods: A comprehensive review was conducted on 13 popular supplements marketed for acne, found through a Google search. Their ingredients, prices, ratings, and existing literature on efficacy and safety were analyzed. A literature review was performed regarding the most common ingredients contained in these supplements.
Results: The most common ingredients in acne supplements were probiotics, diindolylmethane (DIM), vitamin A, vitamin B complex, and zinc. Despite the increasing popularity of dietary supplements, including those for skin health and acne, the absence of FDA regulation and evidence-based data raises concerns about their safety and efficacy. The safety of acne supplement ingredients raises significant worries, with reported cases of thrombotic events and adverse effects, even during pregnancy. The lack of standardized labeling and clear dosing information further complicates the understanding and potential risks of these supplements. Additionally, there is a potential for interactions with other medications, yet this information is often not provided on the product labels.
Limitations: A Google search was used to identify popular acne supplements. Search engine algorithms determine the ranking and presentation of results based on various factors, such as popularity, keywords, as well as user preferences and location, thus posing a potential sampling bias.
Conclusion: It is crucial to exercise caution and prioritize evidence-based information when counseling patients regarding the use of acne supplements.
目的:寻常痤疮是一种常见的皮肤病,针对其发病机理的不同方面可使用各种药物进行治疗。尽管痤疮越来越流行,但美国食品和药物管理局(FDA)并未对市场上销售的用于治疗痤疮的膳食补充剂的安全性和有效性进行评估,这使人们对其标签的真实性产生了怀疑。本综述旨在评估流行的痤疮补充剂成分的安全性和有效性:方法:通过谷歌搜索,对市场上 13 种流行的痤疮补充剂进行了全面审查。分析了这些保健品的成分、价格、评级以及有关功效和安全性的现有文献。此外,还对这些保健品中最常见的成分进行了文献综述:结果:痤疮补充剂中最常见的成分是益生菌、二吲哚甲烷(DIM)、维生素 A、复合维生素 B 和锌。尽管膳食补充剂(包括用于皮肤健康和痤疮的膳食补充剂)越来越受欢迎,但由于缺乏食品及药物管理局的监管和循证数据,人们对其安全性和有效性表示担忧。痤疮补充剂成分的安全性引起了人们的极大担忧,据报道,甚至在怀孕期间也有血栓事件和不良反应的案例。由于缺乏标准化标签和明确的剂量信息,使人们对这些保健品的了解和潜在风险变得更加复杂。此外,这些保健品还有可能与其他药物发生相互作用,但产品标签上往往没有提供这方面的信息:限制:使用谷歌搜索来确定流行的痤疮补充剂。搜索引擎算法会根据各种因素(如流行度、关键词以及用户偏好和位置)来决定搜索结果的排名和呈现方式,因此可能会造成抽样偏差:结论:在向患者提供有关使用痤疮补充剂的咨询时,谨慎行事并优先考虑循证信息至关重要。
{"title":"Evaluating Common Ingredients Contained in Dietary Acne Supplements: An Evidence-Based Review.","authors":"Toral Vaidya, Lauren Hoffman, Anne Chapas","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Acne vulgaris is a common skin condition treated with various medications targeting different aspects of its pathogenesis. Though increasing in popularity, the United States Food and Drug Administration (FDA) does not evaluate the safety or efficacy of dietary supplements marketed for the treatment of acne, calling into question the veracity of their labels. This review aimed to assess the safety and effectiveness of ingredients in popular acne supplements.</p><p><strong>Methods: </strong>A comprehensive review was conducted on 13 popular supplements marketed for acne, found through a Google search. Their ingredients, prices, ratings, and existing literature on efficacy and safety were analyzed. A literature review was performed regarding the most common ingredients contained in these supplements.</p><p><strong>Results: </strong>The most common ingredients in acne supplements were probiotics, diindolylmethane (DIM), vitamin A, vitamin B complex, and zinc. Despite the increasing popularity of dietary supplements, including those for skin health and acne, the absence of FDA regulation and evidence-based data raises concerns about their safety and efficacy. The safety of acne supplement ingredients raises significant worries, with reported cases of thrombotic events and adverse effects, even during pregnancy. The lack of standardized labeling and clear dosing information further complicates the understanding and potential risks of these supplements. Additionally, there is a potential for interactions with other medications, yet this information is often not provided on the product labels.</p><p><strong>Limitations: </strong>A Google search was used to identify popular acne supplements. Search engine algorithms determine the ranking and presentation of results based on various factors, such as popularity, keywords, as well as user preferences and location, thus posing a potential sampling bias.</p><p><strong>Conclusion: </strong>It is crucial to exercise caution and prioritize evidence-based information when counseling patients regarding the use of acne supplements.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3","pages":"34-41"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diplopia Secondary to Neurotoxin Injections: Prevention, Diagnosis, and Management.","authors":"Tara Delle Chiaie","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3-4 Suppl 1","pages":"S30-S36"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ticks are well-known vectors for transmitting disease and cause a variety of cutaneous manifestations to their afflicted host. Tick bite alopecia serves as a lesser-known illustration of this phenomenon, as few cases are documented in the literature. Scarring and nonscarring forms of tick-induced alopecia are described, with the latter being more common. This case highlights an adult female patient who developed a localized oval zone of midparietal scalp hair loss two months after the detection and removal of several ticks on her scalp. The chronicled events, clinical findings, and histopathology results further confirm a particular pattern of manifestation for tick bite alopecia. This case illustrates the importance of recognizing and considering tick bites as a possible cause of focal hair loss, given a similar presentation and historical account.
{"title":"Tick Bite Alopecia in an Adult Female Patient.","authors":"Nathaniel Schaefer, Rania Agha","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ticks are well-known vectors for transmitting disease and cause a variety of cutaneous manifestations to their afflicted host. Tick bite alopecia serves as a lesser-known illustration of this phenomenon, as few cases are documented in the literature. Scarring and nonscarring forms of tick-induced alopecia are described, with the latter being more common. This case highlights an adult female patient who developed a localized oval zone of midparietal scalp hair loss two months after the detection and removal of several ticks on her scalp. The chronicled events, clinical findings, and histopathology results further confirm a particular pattern of manifestation for tick bite alopecia. This case illustrates the importance of recognizing and considering tick bites as a possible cause of focal hair loss, given a similar presentation and historical account.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 3-4 Suppl 1","pages":"S21-S22"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}